Smartwatches and rings are increasingly using AI to turn continuous health data into personalized insights and early risk alerts.
Glucose and ketone monitoring is expanding wearable capabilities and creating new opportunities for continuous metabolic health management.
Clinical evidence, safety, privacy, and reliability will determine whether AI wearables become trusted tools in everyday and clinical healthcare.
A smartwatch once served as a step counter with a few health tools. That role now looks far too narrow. AI-powered wearables can read heart signals, sleep patterns, glucose, ketones, motion, and other body data, then turn those signals into personal health insights. Apple, Samsung, Oura, Abbott, and research groups now push wearables toward early risk alerts, personal baselines, and clinical care.
Apple has placed AI at the center of its latest health strategy. Apple Watch Series 12 and Apple Watch Ultra 4 add a new health sensor system, higher-frequency heart rate and heart rate variability checks, and a new readiness score.
A redesigned Health app also uses Apple Intelligence to turn long-term health and fitness data into more accessible health and longevity insights. A study with more than 1,000 people compared heart rate accuracy across major wearables, and the study showed that the Apple Watch had the highest accuracy.
Samsung has taken a related path. A joint study with Chung-Ang University Gwangmyeong Hospital found that Galaxy Watch6 data could predict vasovagal syncope, a type of syncope, up to five minutes before an episode. The model reached 84.6% accuracy, with 90% sensitivity and 64% specificity. The result shows how wearable data can support early alerts when a model has clinical evidence.
Oura has also moved beyond basic sleep and activity scores. Its Health Radar system can assess cardiovascular and respiratory signals and flag patterns that may need attention. The company has also added health features tied to GLP-1 use.
The business side shows the scale of this market. On September 21, 2026, Oura began its U.S. IPO process with a target fully diluted value of about USD 15.62 billion. Reuters cited revenue of USD 1.21 billion for the nine months ended June 30, 2026, a 74% rise from the same period a year earlier. Oura plans to list on Nasdaq under the symbol OURA.
Also Read - Best Wearable Gadgets for Travel: Smartwatches, Rings, Earbuds
The FDA gave Abbott a major regulatory milestone on August 25, 2026. The agency authorized Abbott’s Libre Duo 10 Day system for people age two and older with diabetes. The device marks the first wearable in the United States with continuous ketone measurement and the first device in the world that can track glucose and ketones together.
The sensor measures both signals every minute, day and night, using fluid beneath the skin. It sends results to a compatible smartphone and can alert users when ketone levels reach a concern threshold. Six clinical studies with more than 600 participants supported the FDA decision.
Research now points toward a more advanced model. A 2026 Nature Sensors review describes AI-powered closed-loop wearable bioelectronics that link real-time body signal capture, AI-based decisions, therapy, and human oversight. The goal goes beyond a simple alert. A future system could detect a change, assess it, and support a timely response.
That path still has major limits. Strong sensors alone cannot prove clinical value. Long-term reliability, safe AI control, clear safeguards, and patient benefit all need solid evidence. Nature Sensors also notes that current devices and many prototypes still keep data collection separate from therapy.
Also Read - Google Brings AI-Powered Insulin Resistance Tracking to Wearables
The biggest test for AI wearables is not the number of sensors inside a watch or ring. The real test is whether a system can turn noisy personal data into safe health guidance. False alerts can create stress, while missed signals can delay care. Privacy also matters as devices collect a detailed record of sleep, heart activity, movement, glucose, and other body signals.
The strongest path for the sector now sits at the point where consumer hardware, clinical evidence, and AI meet. Wearables now offer richer health data than simple fitness trackers. The next step will depend on reliable models, clear medical evidence, and careful limits on what an AI system should claim.
That shift could make the wearable less like a dashboard and more like a personal health layer that supports earlier action. That change gives the category a role inside everyday health care and clinical support.
1. What are AI-powered wearables?
AI-powered wearables are devices such as smartwatches and smart rings that use sensors and AI to analyze health data and provide personalized insights or alerts.
2. How can AI wearables support preventive healthcare?
They can continuously monitor health signals, identify changes from personal baselines, and potentially provide earlier warnings that encourage timely medical attention.
3. Can wearables monitor glucose and ketones?
Yes. Newer wearable systems can continuously measure glucose and, in some cases, ketones, adding metabolic information alongside traditional health metrics.
4. Are AI wearable alerts medically reliable?
Reliability varies by device and use case. Clinical validation, long-term evidence, accuracy, and appropriate medical safeguards are essential before treating an alert as clinically meaningful.
5. What is the future of AI-powered healthcare wearables?
The sector is moving toward systems that combine continuous sensing, AI analysis, personalized recommendations, and potentially closed-loop therapeutic support under appropriate human and clinical oversight.